NIH PAR · NIA · R01
PAR-25-374: Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
- NOFO number
- PAR-25-374
- Type
- PAR
- Activity code
- R01
- Primary institute
- NIA · National Institute on Aging
- Clinical trials
- Not Allowed
- Posted
- Dec 30, 2024
- Opens
- May 9, 2025
- Expires
- May 8, 2028
PAR-25-374 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| June 09, 2025 | July 09, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 06, 2025 | November 06, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 06, 2026 | March 06, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 09, 2026 | July 09, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 06, 2026 | November 06, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 08, 2027 | March 08, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 09, 2027 | July 09, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 08, 2027 | November 08, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 07, 2028 | March 07, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
Projects funded under PAR-25-374
NIH RePORTER lists 3 projects funded under PAR-25-374 in FY2022–FY2026, with $3.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$3.4M
Award dollars under PAR-25-374, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 2 | $3.4M |
Institutions with the most funding
- University of California, San Francisco$1.4M · 1 project
- Sloan-Kettering Inst Can Research$1.2M · 1 project
- Cleveland Clinic Lerner Com-Cwru$781K · 1 project
Funding institutes
- NIA$3.4M · 3
Activity codes funded
- R013 records
Most recent new awards
- Restoring Drug Responsiveness in Alzheimer’s Disease by Repairing Target Architecture (opens NIH RePORTER)
Sloan-Kettering Inst Can Research · 1R01AG102339-01 · NIA · Notice Aug 25, 2026
$1.2MR01
- Cell Type Specific Drug Repurposing for Alzheimer's Disease (opens NIH RePORTER)
University of California, San Francisco · 1R01AG100879-01 · NIA · Notice May 21, 2026
$1.4MR01
What its predecessor PAR-20-156 funded
PAR-25-374 reissues PAR-20-156. Its funding history is the best guide to who wins under this program: 18 projects and $46.8M in FY2022–FY2026.
Projects funded
18
Distinct projects, FY2022–FY2026
New awards
10
Type 1 (new project) award records
NIH funding
$46.8M
Award dollars under PAR-20-156, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 12 | 7 | $8.8M |
| FY2023 | 13 | 1 | $9.7M |
| FY2024 | 15 | 2 | $11.3M |
| FY2025 | 15 | 0 | $9.5M |
| FY2026 | 13 | 0 | $7.6M |
Institutions with the most funding
- Weill Medical Coll of Cornell Univ$6.5M · 2 projects
- J. David Gladstone Institutes$4.7M · 1 project
- Cleveland Clinic Lerner Com-Cwru$4.0M · 1 project
- Massachusetts General Hospital$3.9M · 1 project
- University of Minnesota$3.8M · 1 project
- University of Pennsylvania$3.8M · 2 projects
- George Washington University$3.4M · 1 project
- Methodist Hospital Research Institute$3.1M · 1 project
Funding institutes
- NIA$46.8M · 68
Activity codes funded
- R0163 records
- R565 records
Most recent new awards
- Systematically screening and validating drug repurposing candidates for Alzheimer's Disease and Related Dementias (opens NIH RePORTER)
Vanderbilt University Medical Center · 1R56AG084550-01 · NIA · Notice Sep 18, 2024
$875KR56
- Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease (opens NIH RePORTER)
Brigham and Women's Hospital · 1R01AG084531-01 · NIA · Notice Jan 25, 2024
$859KR01
- Drugs repositioning to target TREM2 in Alzheimer disease (opens NIH RePORTER)
University of Alabama at Birmingham · 1R01AG081228-01 · NIA · Notice Jun 14, 2023
$611KR01
- SmartAD for Intelligent Alzheimer’s Disease(AD) Personalized Combination Therapy (opens NIH RePORTER)
University of Pittsburgh at Pittsburgh · 1R56AG074951-01A1 · NIA · Notice Sep 8, 2022
$395KR56
- Detecting synergistic effects of pharmacological and non-pharmacological interventions for AD/ADRD (opens NIH RePORTER)
University of Minnesota · 1R01AG078154-01 · NIA · Notice Aug 24, 2022
$782KR01
- Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use (opens NIH RePORTER)
J. David Gladstone Institutes · 1R01AG078164-01 · NIA · Notice Aug 18, 2022
$942KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-374. Contact the program officer at the institute that fits your research before applying.
- NIA · National Institute on Aging
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are capped at 1 million in direct costs per year. Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIA intends to commit 6 million in FY 2026 to fund 4 - 5 awards.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-20-156.
Other open NOFOs for R01
- PAR-27-090Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional)NIA · next due Feb 5, 2027
- PAR-27-081Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)NIA · next due Feb 5, 2027
- PAR-25-279New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)NIA · next due Feb 5, 2027
- PAR-25-379Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)NIDA · next due Oct 21, 2026
- PAR-25-322Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)OD · next due Jan 26, 2027
- PA-25-301NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)NIH · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.